Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stemline Therapeutics Inc Announces Presentations Of SL-401 Updated Clinical Trial Results In Acute Myeloid Leukemia And Blastic Plasmacytoid Dendritic Cell Neoplasm


Friday, 7 Dec 2012 08:30am EST 

Stemline Therapeutics Inc announced that two studies featuring SL-401 updated clinical trial results in acute myeloid leukemia (AML) and other hematologic malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), and SL-101 preclinical activity against Hodgkin's lymphoma have been selected for presentation at the upcoming 54 th Annual Meeting of the American Society of Hematology (ASH) to be held in Atlanta, GA from December 8-11, 2012 . Stemline and its collaborators from MD Anderson Cancer Center and Scott and White Memorial Hospital will present the posters. The updated clinical trial results for SL-401, a novel biologic targeted therapy directed to the interleukin-3 receptor (IL-3R), demonstrated that the drug was well-tolerated at clinically active doses and showed single agent anti-tumor activity in heavily pretreated patients with AML, as well as in patients with high risk myelodysplastic syndrome (MDS) and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). In particular, a single cycle of SL-401 demonstrated single agent activity in patients with relapsed or refractory AML, including two durable complete responses (CRs) of eight and >25 months duration, respectively, and multiple additional cases of leukemia blast reductions. 

Company Quote

12.79
-0.06 -0.47%
22 Oct 2014